NEA 17 Amends Korro Bio Stake Filing

TL;DR

NEA 17 just updated its Korro Bio filing - watch this space.

AI Summary

New Enterprise Associates 17, L.P. (NEA 17) filed an amendment to its Schedule 13D on April 24, 2024, regarding its holdings in Korro Bio, Inc. The filing indicates a change in the group members and their reporting obligations. NEA 17, a significant investor, is updating its disclosures related to its stake in Korro Bio, a company formerly known as Frequency Therapeutics, Inc.

Why It Matters

This amendment signals a potential shift in the investment landscape for Korro Bio, as a major shareholder updates its disclosures, which could influence market perception and trading activity.

Risk Assessment

Risk Level: medium — Schedule 13D filings often precede significant corporate actions or shifts in control, which can introduce volatility.

Key Players & Entities

• New Enterprise Associates 17, L.P. (company) — Filing entity
• Korro Bio, Inc. (company) — Subject company
• Frequency Therapeutics, Inc. (company) — Former name of subject company
• NEA 17 GP, LLC (company) — Group member
• NEA PARTNERS 17, L.P. (company) — Group member
• ALI BEHBAHANI (person) — Group member
• ANTHONY A. FLORENCE, JR. (person) — Group member
• CARMEN CHANG (person) — Group member
• EDWARD T. MATHERS (person) — Group member
• FOREST BASKETT (person) — Group member

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securiti
• $0.001 — 17, 2023, relating to the common stock, $0.001 par value (the “Common Stock&rdqu
• $56.00 — of Common Stock at a purchase price of $56.00 per share from the Issuer in a private
• $999,992.00 — tion for an aggregate purchase price of $999,992.00 (the “2024 Private Placement&rdqu

Filing Documents

• nea17-korro_18823.htm (SC 13D/A) — 446KB
• 0001072613-24-000402.txt ( ) — 448KB

Purpose

Item 4. Purpose of Transaction . NEA 17 agreed to acquire the NEA 17 Shares for investment purposes. Subject to the Lock-Up Agreement, Registration Rights Agreement, and the 2024 Registration Rights Agreement (as defined below) and depending on market conditions, NEA 17’s continuing evaluation of the business and prospects of the Issuer and other factors, NEA 17 and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer’s business or corporate structure; (g) Changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (j) Any action similar to any of those enumerated above. CUSIP No.500946108 13D Page 16 of 22

View Full Filing

View this SC 13D/A filing on SEC EDGAR